Clinical Trial: Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Observational
Official Title: Calciphylaxis : Population, Risk Factors, Diagnostic Practice, Therapeutic and Outcome : a Multicentric, Retrospective Cohort
Brief Summary:
Calciphylaxis, also called Calcific Uremic Arteriolopathy (CUA) is a lethal affection mostly affecting patient in end stage renal disease. The survival rate is described around 20 to 46% at one year.
Clinical presentation is very painful skin lesions with ulceration mostly located on the trunk or thigh.
Current knowledge about physiopathology, diagnostic practice and therapeutic is very limited.
Actually there is no European study about calciphylaxis and risk factors, diagnostic practice and outcome factors.
Detailed Summary:
Sponsor: Nantes University Hospital
Current Primary Outcome: Description of calcific uremic arteriolopathy in a French population by describing the characteristics of the population, diagnostic and treatment practices and patient outcome. [ Time Frame: Up to 16 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
- Study factors determining the patient outcome with calciphylaxis [ Time Frame: Up to 16 months ]
- Study case control of risk factors in the subgroup of patients in extra renal replacement therapy [ Time Frame: Up to 16 months ]
Original Secondary Outcome: Same as current
Information By: Nantes University Hospital
Dates:
Date Received: July 26, 2016
Date Started: August 2016
Date Completion: November 2017
Last Updated: July 29, 2016
Last Verified: July 2016
